Market Insights - Page 2

Bispecific-Antibody-Pipeline-Insights

Bispecific Antibody Pipeline Drugs and Companies Insight Report, 2025: Clinical, Commercial, and Developmental Analysis

(Las Vegas, Nevada, United States) According to DelveInsight’s latest evaluation, the global bispecific antibody pipeline includes more than 180 active companies collectively developing over 250 bispecific antibody–based therapeutic candidates. The pipeline analysis provides a detailed overview of clinical trials, therapeutic approaches, mechanisms
4 February 2026
Complicated-Urinary-Tract-Infection-Market-Insights

Complicated Urinary Tract Infection Market Forecast to 2034 Shows Strong Growth, Driven by Antibiotic Innovation and Rising Disease Burden

The Complicated Urinary Tract Infection (cUTI) market is expected to witness substantial growth through 2034, supported by rising disease prevalence, increasing antimicrobial resistance (AMR), and a robust late-stage antibiotic pipeline, according to DelveInsight’s Complicated Urinary Tract Infection Market Insights, Epidemiology, and Forecast
4 February 2026
Invasive-Aspergillosis-Market-Insights

Invasive Aspergillosis Market Outlook Signals Sustained Growth to 2034

DelveInsight’s report titled “Invasive Aspergillosis Market Insights, Epidemiology, and Market Forecast – 2034” provides a comprehensive analysis of invasive aspergillosis, covering historical and projected epidemiology trends along with market dynamics across the United States, EU4 (Germany, France, Italy, and Spain), the United
4 February 2026
Autism-Spectrum-Disorder-Pipeline-Insights

Autism Spectrum Disorder Pipeline Insight 2025: Emerging Therapies, Clinical Trial Updates, and Regulatory Progress

The Autism Spectrum Disorder (ASD) Pipeline Insight 2025 highlights a rapidly evolving therapeutic landscape, driven by increasing disease prevalence, advances in neurodevelopmental research, and growing investment in precision medicine. According to DelveInsight, more than 18 biopharmaceutical companies are actively developing 20+ investigational
4 February 2026